Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Defence Therapeutics ( (TSE:DTC) ) just unveiled an announcement.
Defence Therapeutics Inc. has successfully closed the second tranche of its non-brokered private placement, raising $3.915 million through the issuance of units consisting of common shares and share purchase warrants. The proceeds will be utilized to advance the company’s preclinical and clinical programs and for general working capital. This financial boost is expected to enhance Defence’s capabilities in the biotechnology sector, supporting its ongoing development of next-generation radio-immuno-conjugate and ADC products.
More about Defence Therapeutics
Defence Therapeutics is a publicly-traded, Canadian biopharmaceutical company focused on developing radiopharmaceuticals and antibody-drug conjugates (ADCs) using its proprietary platform and drug delivery technologies. The company is also working on novel immune-oncology vaccines, with its core ACCUM® technology enhancing the precision delivery of these products to target cells, thereby increasing efficacy against diseases such as cancer and infectious diseases.
YTD Price Performance: 92.31%
Average Trading Volume: 23,686
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $36.73M
For detailed information about DTC stock, go to TipRanks’ Stock Analysis page.
